💧 CBD Drug Interaction Liver Enzyme Simulator

Baseline Liver Function Before CBD Therapy

Normal transaminase levels establish a pre-treatment reference point.

• 7–56: Normal ALT (U/L reference range)
• 8–48: Normal AST (U/L reference range)
• Required: Baseline panel (before starting therapy)
• Healthy: Hepatocyte state (no cellular stress)

Why a baseline liver panel matters

Establishes each patient's normal ALT/AST before any CBD exposure.

Hepatocyte physiology at rest

Healthy hepatocytes process metabolic load without enzyme leakage.

Initiating Epidiolex-Level CBD Dosing

High-dose CBD begins, frequently alongside valproate antiepileptic therapy.

• 10–20: Epidiolex dose range (mg/kg/day typical)
• Valproate: Common co-med (antiepileptic drug)
• Yes: FDA label warning (transaminase elevation risk)
• Weeks 1–4: Onset window (highest risk period)

Dose titration in clinical practice

CBD is titrated upward toward target maintenance dose over weeks.

Why valproate co-therapy is common

Both drugs treat epilepsy, so combined use is frequent in practice.

CBD Inhibits CYP450 and Alters Valproate Clearance

Shared enzyme pathways mean CBD slows valproate metabolism, adding hepatic stress.

• CYP2C19/3A4: Key enzymes (inhibited by CBD)
• Reduced: Valproate clearance (when CBD co-administered)
• Pharmacokinetic: Interaction type (competitive enzyme inhibition)
• Increased: Hepatocyte load (dual substrate burden)

CYP450 pathway competition

CBD and valproate compete for the same hepatic metabolizing enzymes.

Downstream metabolic stress

Slower clearance raises drug exposure and cellular workload.

Liver Enzyme Elevation Develops in a Subset of Patients

ALT/AST rise above normal, more common at higher CBD doses with valproate.

• ~13%: Transaminitis incidence (trial patients, CBD+VPA)
• >3× ULN: Threshold flagged (upper limit of normal)
• Higher: Risk multiplier (CBD + valproate combo)
• Often none: Symptom presence (labs catch it first)

Dose-dependent enzyme rise

Higher CBD dose correlates with greater transaminase elevation.

Combined-risk with valproate

Co-administration meaningfully raises the elevation rate.

FDA label: check LFTs before, then during CBD plus valproate.

Routine Monitoring Enables Early Detection and Recovery

Periodic ALT/AST checks catch elevation early; enzymes often normalize after adjustment.

• Baseline+periodic: Monitoring schedule (per FDA label)
• Often reverses: Response to dose cut (ALT/AST normalize)
• Low: Discontinuation rate (most managed by dose change)
• Weeks: Recovery timeframe (after adjustment)

Standard monitoring protocol

Labs at baseline, then at set intervals during high-dose therapy.

Outcomes after intervention

Dose reduction or discontinuation usually restores normal enzymes.